Περίληψη:
Primary hyperparathyroidism (pHPT), which most frequently occurs asymptomatically, is a common endocrine disease associated with increased morbidity and mortality. The newly introduced management guidelines as well as the recent availability of the first calcimimetic offer a highly promising therapeutic option for patients with pHPT. Cinacalcet, the first available calcimimetic, increases the sensitivity of the calcium-sensing receptor (CaR) to circulating serum calcium, thereby safely reducing serum calcium and PTH concentrations in patients with mild-tomoderate pHPT, intractable disease, and also parathyroid carcinoma. Cinacalcet has proved efficient in short-and long-term controls of hypercalcemia and, though bone mineral density was not improved, the available data point to cinacalcet as the treatment of choice in non-operable patients with pHPT. These results encompass a wide spectrum of disease severity. Results are pending as to whether cinacalcet decreases mortality and morbidity in pHPT, confirmation of which would conclusively recommend this drug as a valid alternative to surgery. © Springer Science+Business Media, LLC 2011.
Λέξεις-κλειδιά:
1,25 dihydroxyergocalciferol; alendronic acid; bisphosphonic acid derivative; calcimimetic agent; calcium; calcium sensing receptor; cinacalcet; cyclin D1; ibandronic acid; pamidronic acid; parathyroid hormone; placebo; raloxifene; selective estrogen receptor modulator; Wnt protein; zoledronic acid, Albright syndrome; alternative medicine; bone density; calcium blood level; cardiovascular risk; deep vein thrombosis; disease severity; dose response; drug cost; drug dose titration; drug efficacy; drug mechanism; drug safety; drug tolerability; human; hypercalcemia; morbidity; mortality; multiple endocrine neoplasia; pathogenesis; primary hyperparathyroidism; priority journal; review; secondary hyperparathyroidism; thrombophlebitis; treatment duration; treatment indication
